Background: Medical phototherapy can lead to the manifestation of polymorphic light eruption (PLE), though little is known about the frequency of such events.
| INTRODUC TI ON
Polymorphic light eruption (PLE) is the most common photodermatosis and is especially prevalent among young women in temperate climates. 1 Severely affected individuals, who experience repeated attacks of PLE throughout the summer, may require prophylactic medical photohardening each spring before the first intense sun exposure. Medical photohardening simulates the naturally occurring phenomenon of hardening and aims to induce photoadaption. Broadband UVB (290-320 nm) (BB-UVB), narrowband UVB (311-313 nm) (NB-UVB), and psoralen plus UVA (PUVA) photochemotherapy are effective in photohardening of PLE. [2] [3] [4] [5] [6] [7] Although it is well known that medical phototherapy can lead to PLE, little is known about the frequency of such events. The aim of this study was to investigate the frequency of PLE under prophylactic photohardening in PLE-prone patients. Additionally, we investigated the
| Statistical analysis
Descriptive data from our analyses were presented in tables. The
Fisher exact or chi-square test, as appropriate, was used to compare the prevalence of PLE under phototherapy between different groups of patients. A P value P < 0.05 was considered significant.
| RE SULTS
Our electronic database search identified the occurrence of PLE under photohardening (in any cycle) in 24.3% (18/74) of PLE patients (Table 1) . Photohardening with suberythemal dosages of NB-UVB had been administered to all PLE patients during phototherapy treatment cycles 2-3 times per week for 4-6 weeks in spring, at a starting dose of 0.2 J/cm 2 and in dose increments of 0.05-0.1 J/cm 2 per treatment, as tolerated. 8 The other forms of phototherapy had been administered to the PLE patients, as previously described. 7 The frequency of PLE in patients with other diseases treated with minimal photoxic dose-or skin phototype-based suberythemal phototherapy ranged from 0.4% (psoriasis) to 16.7% (PLEVA). PLE occurred significantly more often in PLE-prone patients who underwent photohardening than in psoriasis patients who underwent phototherapy (P < 0.0001). Compared with its occurrence in patients with psoriasis (the disease with the lowest observed prevalence of PLE), PLE occurred significantly more often under phototherapy in patients with parapsoriasis en plaques/mycosis fungoides (3.5%, P = 0.0206), granuloma anulare (7.4%, P = 0.0013), scleroderma (14.3%, P = 0.0002), and PLEVA (16.7%, P < 0.0001) ( Table 1 ). The frequency of PLE in patients with atopic eczema and prurigo was low and did not differ statistically from that in patients with psoriasis. PLE occurrence did not appear to be affected by wavebands or phototherapeutic modalities administered to the patients ( Table 1 ).
The demographics and phototherapy characteristics of PLE patients undergoing phototherapy are presented for individual patients in Table 2 and then summarized in Table 3 . Under daily life conditions and exposure to natural sunlight, more women than men experienced PLE under photohardening (ie, 16 vs 2) (Table 1) , consistent with the observation that more women than men overall had undergone photohardening. Surprisingly, however, the female/male ratio in non-PLE patients (7/9) was more balanced, despite a similar overall number of phototherapy-treated women and men in non-PLE patient groups. Besides, there were no major differences in phototherapy characteristics between PLE patients and non-PLE patients.
For instance, in PLE patients, the disease manifested after a median of five treatment exposures in the first cycle of occurrence, compared with 5.5 treatment exposures in non-PLE patients (Table 3 ). In general, the occurrence of PLE in a patient did not result in a change of the allocated standard treatment protocol, though some of them received short-term topical steroids to mitigate the rash.
| D ISCUSS I ON
In this Austrian study, PLE occurred in 24% (18/74) of PLE patients under photohardening, a percentage considerably lower than the 56% (44/79) recently reported in a 5-year single-center, case-series review from Scotland. 5 The reasons for this difference remain elusive, but may be partly due to differences in phototherapy treatment protocols and/or skin phototype. In our study, the minority (21%, seems to be highly linked to photosensitive variants of psoriatic disease. In an epidemiologic study, 43% of all patients suffering from photosensitive psoriasis were found to have a history of PLE with secondary exacerbation of psoriatic lesions. 10 We recently speculated that resistance to UV-induced immune suppression in PLE may photoaggravate other diseases such as coexisting psoriasis, which commonly responds beneficially to UV radiation from sunlight or artificial sources. 9 Psoriasis patients who are susceptible to PLE may not experience the beneficial antipsoriatic effects of UVB but may instead experience induction and/or worsening of psoriatic disease after UVB exposure. In these patients, UVB radiation may induce innate immunity through antimicrobial peptides such as cathelicidin LL-37, resulting in psoriatic lesions when there is simultaneous resistance to the UV-induced suppression of the adaptive immune response (like in PLE) that would normally counteract such lesions. 9 Thus, patients with photosensitive psoriasis may not be allocated to UVB phototherapy (based on a history of photoaggravation that is possibly linked to PLE), which may in turn explain the very low prevalence of PLE in our series of psoriasis patients. In contrast, PUVA may act in photosensitive psoriasis without provoking PLE, 11, 12 consistent with our data showing that none of 133 psoriatic patients treated with PUVA developed PLE during treatment (Table 1) .
TA B L E 3 Summary of demographics and treatment characteristics of patients with PLE eruption occurring under phototherapy
However, we observed a relatively high frequency of PLE under phototherapy in patients with parapsoriasis en plaques/mycosis fungoides (3.5%), granuloma anulare (7.4%), scleroderma (14.3%), and PLC/PLEVA (16.7%). This may be due to differences in pathophysiology and immunological hyperresponsiveness to UV radiation between these conditions and non-photosensitive psoriasis. We observed PLE in a few non-PLE patients after UVA1 (340-400 nm) treatment, including one patient with scleroderma. PLE seems to be induced more often by UVA (320-400 nm) than by UVB (290-320 nm), but can also be induced by UVB alone and sometimes by both wavebands together (cited in 2 ). The role of UVA in triggering PLE has been well substantiated by phototest findings and the observation that most patients with PLE are sensitive to sunlight through window glass (cited in 2 ) and by the observed lack of protection from pure UVB-absorbing sunscreens. 13 Although the generalizability of our study's findings is limited by the rather low patient numbers in some of the diseases examined and by the retrospective study design, our findings do suggest that PLE manifestation under photohardening occurs frequently in PLE-prone patients but variably in other diseases treated with phototherapy. This knowledge will be helpful for allocating treatment, estimating risk of PLE occurrence, and obtaining related informed consent not only from PLE-prone patients but also from patients with other skin disorders commonly treated with phototherapy.
